1 Ocak 2019 Dergi makalesi Açık Erişim

Bulbul, Mehmet; Sinen, Osman; Ozkan, Ayse; Aslan, Mutay Aydin; Agar, Aysel

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <controlfield tag="001">112332</controlfield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="v">317</subfield>
    <subfield code="p">EXPERIMENTAL NEUROLOGY</subfield>
    <subfield code="c">78-86</subfield>
  </datafield>
  <controlfield tag="005">20210420143202.0</controlfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Parkinson's disease (PD) is characterized by degeneration of the dopaminergic neurons in substantia nigra (SN). The motor symptoms of PD include tremor, rigidity, bradykinesia and postural impairment. In rodents, central administration of neuropeptide-S (NPS) has been shown to induce locomotor activity, dopamine release and neuronal survival by decreasing lipid peroxidation, additionally, the NPS receptor (NPSR) was detected in SN. Accumulating findings suggest that central NPS may ameliorate the parkinsonian symptoms, however, this has been explored incompletely due to the scarcity of experimental studies. Therefore, the present study was designed to test whether central NPS treatment exerts protective and/or alleviative effects on 6-OHDA-induced rat experimental PD model. Adult male Wistar rats received acute (alleviate; 10 nmol, icv) or chronic (protective; 1 nmol, icv for 7 days) NPS treatment following the central injection of 6-OHDA in medial forebrain bundle. Motor performance tests and in vivo nigral microdialysis were performed before and 7 days after the central 6-OHDA injection. The immunoreactivities for tyrosine hydroxylase (TH), NPSR, 4-hydroxynonenal (4-HNE) and c-Fos were detected by immunohistochemistry in frozen SN sections. Our double immunofluorescence labeling studies demonstrated that NPSR is present in the nigral TH-positive neurons. Central NPS injection caused a remarkable c-Fos expression in SN; whereas, no change was observed following vehicle injection. In both chronic and acute treatment groups, the 6-OHDA-induced motor dysfunction and impaired nigral dopamine release were improved significantly. However, only chronic, but not acute treatment restored the loss of nigral TH-positive cells, while decreasing the 4-HNE immunoreactivity in SN. Our findings demonstrate that central NPS treatment not only exerts a neuroprotective action on nigral dopaminergic neurons, it also improves the striatal dopaminergic signaling. Therefore, the present study candidates the NPSR agonism as a novel therapeutic approach for PD treatment.</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
    <subfield code="o">oai:zenodo.org:112332</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Akdeniz Univ, Dept Physiol, Fac Med, Antalya, Turkey</subfield>
    <subfield code="a">Bulbul, Mehmet</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="z">md5:bc5b45dcc4ad0b35fa5ddaf23531a84d</subfield>
    <subfield code="s">198</subfield>
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/112332/files/bib-8884b3fd-6fe6-496f-bb22-befcdfa6ffa3.txt</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="2">doi</subfield>
    <subfield code="a">10.1016/j.expneurol.2019.02.015</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Akdeniz Univ, Dept Physiol, Fac Med, Antalya, Turkey</subfield>
    <subfield code="a">Sinen, Osman</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Akdeniz Univ, Dept Physiol, Fac Med, Antalya, Turkey</subfield>
    <subfield code="a">Ozkan, Ayse</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Akdeniz Univ, Dept Med Biochem, Fac Med, Antalya, Turkey</subfield>
    <subfield code="a">Aslan, Mutay Aydin</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Akdeniz Univ, Dept Physiol, Fac Med, Antalya, Turkey</subfield>
    <subfield code="a">Agar, Aysel</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2019-01-01</subfield>
  </datafield>
</record>